At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 56 enrolled
Drug / intervention
MK-8245 +1 moredrug
Likely dose
MK-8245 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacokinetics of MK-8245 in Subjects With Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating MK-8245 and Comparator: placebo for Type 2 Diabetes Mellitus. Completed, enrolled 56 participants.
Detailed Summary
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes. The primary hypothesis of the study is that after 4 weeks of treatment, MK-8245 produces a greater reduction in 24 hour weighted mean glucose (WMG) from baseline than placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedSep 2009
Primary CompletionJan 2010
Study CompletionJan 2010
TodayJul 2026
First PostedSep 4, 2009
Enrollment StartAug 24, 2009
Primary CompletionJan 12, 2010
Study CompletionJan 26, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.8 years ago
Interventions
MK-8245drug
MK-8245 50 mg twice daily for 28 days
Comparator: placebodrug
matching placebo to MK-8245 twice daily for 28 days